Blog
>
News
>
EO Care, Inc. Statement on Cannabinoid Policy Announcements

EO Care, Inc. Statement on Cannabinoid Policy Announcements

The Administration’s decision to move to reclassify cannabis from Schedule I to Schedule III is a watershed moment for adult Americans who currently or might benefit from the responsible use of cannabinoids, especially oncology patients and older adults. It’s a long overdue step that will reduce stigma, open doors for essential research and product development, and increase access to care for patients.

Learn More About EO's Products

Every EO product is clinician-designed and precisely dosed. Inhalers, gummies, tablets, tinctures, topicals, and beverage shots. They ship straight to your door, no dispensary needed.

Responsibly Made & Tested

  • ✓ 100% organic hemp, no synthetics
  • ✓ Produced at GMP-certified facilities
  • ✓ 3rd-party tested for accuracy/safety

Federally Legal

  • ✓ <0.3% hemp-derived THC
  • ✓ Farm Bill compliant
  • ✓ Ships to your door like any package

Expert Guidance Included

  • ✓ Ensure optimal dosing
  • ✓ Minimize side effects
  • ✓ Use safely and wisely
Explore

EO Care commends the Administration’s decision to move to reclassify cannabis from Schedule I to Schedule III. This decision is a watershed moment for adult Americans who currently or might benefit from the responsible use of cannabinoids, especially oncology patients and older adults. It’s a long overdue step that will reduce stigma, open doors for essential research and product development, and increase access to care for patients.

‍

We also commend the Administration for their support of a safe and well-regulated hemp-derived cannabinoid industry. Such products already provide relief to millions and should be readily accessible to adults seeking to manage chronic pain, stress, sleep issues and cancer-related symptoms.

‍

The rescheduling announcement and related hemp announcements will help cannabinoids find their rightful place in the practice of evidence-based medicine and eventually help enable reimbursement through employer benefit and payer plan coverage.

‍

As the details of rescheduling and hemp policy continue to be finalized, EO is uniquely positioned to push cannabinoid-based research and care forward via the company’s personalized, clinically responsible cannabinoid guidance and data platform and via its clinically formulated cannabinoid products for pain, sleep, stress and appetite stimulation.

‍

We look forward to continuing to serve patients and clinicians at leading hospitals and NCI-Designated Cancer Centers across the country. And we look forward to partnering closely with all relevant Federal agencies and playing a key role in the collection and analysis of detailed cannabinoid efficacy, safety and cost of care data.

‍

About EO Care, Inc. EO is the leader in cannabinoid-based symptom management. The company provides personalized, clinically responsible care through its unique, scalable digital health platform and affordable, medicalized and federally legal hemp-derived cannabinoid products. Board members, advisors and investors include Regina Benjamin, MD, MBA, former Surgeon General of the United States; Kristi Savacool, former CEO of AON Hewitt; and Bill Van Faasen, former CEO of Blue Cross Blue Shield Massachusetts. For more information, visit eo.care.

‍

These statements have not been evaluated by the Food and Drug Administration. This page is not intended to diagnose, mitigate, treat, cure, or prevent any disease.

Free Care Plans? Of Course.

Everyone deserves personalized, clinically responsible cannabis guidance. Tell us about your symptoms, get a plan from our clinician-led team, and message them anytime. Free, with up to 20% off the products in your plan.

Get a Free Care Plan
More
News
News

EO Care Joins Mayo Clinic Platform Accelerate October 2026 Cohort

We’re excited to share that EO Care has joined the October 2026 Mayo Clinic Platform Accelerate cohort. Through Accelerate, participating companies gain access to Mayo Clinic Platform’s de-identified clinical data ecosystem, mentorship from Mayo Clinic experts, and education on clinical and business topics. Since launching in 2022, the program has supported more than 130 companies from around the world.

Read More
Read More
News

EO Care Joins the Personify Health Partner Marketplace, Expanding Employer Access to Clinically Guided Cancer Symptom Management Solution

Employers using Personify Health can choose clinically responsible, evidence-based cannabinoid care to reduce unmanaged symptom burden, prescription reliance, and avoidable healthcare costs

Read More
Read More
News

EO Data & Methodology: September 2026 Update

At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from people living with cancer who use cannabis to manage symptoms such as pain, sleep disturbance and anxiety, under the guidance of our clinical protocols.

Read More
Read More